$1.68 EPS Expected for Icon Plc (NASDAQ:ICLR) This Quarter

Analysts expect that Icon Plc (NASDAQ:ICLR) will announce $1.68 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Icon’s earnings, with the highest EPS estimate coming in at $1.71 and the lowest estimate coming in at $1.66. Icon reported earnings of $1.51 per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 11.3%. The firm is expected to announce its next earnings report on Wednesday, July 24th.

According to Zacks, analysts expect that Icon will report full-year earnings of $6.87 per share for the current year, with EPS estimates ranging from $6.83 to $6.90. For the next financial year, analysts anticipate that the business will report earnings of $7.66 per share, with EPS estimates ranging from $7.50 to $7.91. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Icon.

Icon (NASDAQ:ICLR) last announced its quarterly earnings data on Wednesday, May 1st. The medical research company reported $1.63 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.60 by $0.03. The company had revenue of $674.85 million during the quarter, compared to analyst estimates of $668.93 million. Icon had a net margin of 12.56% and a return on equity of 25.71%. The firm’s revenue for the quarter was up 8.8% compared to the same quarter last year. During the same period last year, the business earned $1.44 EPS.

Several brokerages have weighed in on ICLR. Zacks Investment Research raised shares of Icon from a “hold” rating to a “buy” rating and set a $157.00 price objective for the company in a report on Thursday, May 30th. BidaskClub raised shares of Icon from a “sell” rating to a “hold” rating in a report on Thursday, June 27th. Finally, ValuEngine lowered shares of Icon from a “buy” rating to a “hold” rating in a report on Tuesday, April 16th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company. Icon presently has a consensus rating of “Buy” and a consensus target price of $156.63.

ICLR stock traded down $0.58 during mid-day trading on Wednesday, hitting $151.52. 6,283 shares of the company were exchanged, compared to its average volume of 288,713. The firm has a market cap of $8.21 billion, a P/E ratio of 24.17, a PEG ratio of 2.12 and a beta of 0.56. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.02 and a quick ratio of 2.02. Icon has a twelve month low of $118.10 and a twelve month high of $156.34. The stock’s fifty day moving average is $146.04.

Several hedge funds and other institutional investors have recently bought and sold shares of ICLR. Ellis Investment Partners LLC acquired a new position in shares of Icon in the 1st quarter valued at about $59,000. NumerixS Investment Technologies Inc acquired a new position in shares of Icon in the 4th quarter valued at about $64,000. O Shaughnessy Asset Management LLC acquired a new position in shares of Icon in the 4th quarter valued at about $132,000. Captrust Financial Advisors boosted its holdings in shares of Icon by 85.4% in the 4th quarter. Captrust Financial Advisors now owns 1,472 shares of the medical research company’s stock valued at $190,000 after buying an additional 678 shares during the period. Finally, First Allied Advisory Services Inc. acquired a new position in shares of Icon in the 1st quarter valued at about $207,000. 85.73% of the stock is owned by institutional investors and hedge funds.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Recommended Story: Capital Gains Distribution

Get a free copy of the Zacks research report on Icon (ICLR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.